-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Aspirin in Mucocutaneous Lymph Node Syndrome (Kawasaki Disease)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Aspirin in Mucocutaneous Lymph Node Syndrome (Kawasaki Disease)Drug Details:Aspirin is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Defibrotide Sodium in Mucocutaneous Lymph Node Syndrome (Kawasaki Disease)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Defibrotide Sodium in Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Drug Details: Defibrotide sodium (Noravid, Defitelio,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SND-002 in Metastatic Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SND-002 in Metastatic Melanoma Drug Details:SND-002 (Sentoclone) is under development for the treatment of malignant melanoma...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Hyaluronidase (Recombinant Human) + Pertuzumab + Trastuzumab) in Breast Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.(Hyaluronidase (Recombinant Human) + Pertuzumab + Trastuzumab) in Breast CancerDrug Details:Hyaluronidase (recombinant human), pertuzumab and trastuzumab...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CreaVax-BC in Glioblastoma Multiforme (GBM)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CreaVax-BC in Glioblastoma Multiforme (GBM) Drug Details:Creavax-BC is under development for the treatment of glioblastoma multifrome....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Cutaneous Squamous Cell Carcinoma (cSCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Cutaneous Squamous Cell Carcinoma (cSCC) Drug Details: RP-1 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Colorectal Cancer Drug Details: RP-1 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Melanoma Drug Details: RP-1 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Bladder Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Bladder Cancer Drug Details: RP-1 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Esophageal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Esophageal Cancer Drug Details: RP-1 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Metastatic Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Metastatic Breast Cancer Drug Details: RP-1 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Nonmelanomatous Skin Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Nonmelanomatous Skin Cancer Drug Details: RP-1 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Drug Details: RP-1 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Merkel Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Merkel Cell Carcinoma Drug Details: RP-1 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Angiosarcoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene oderparepvec in Angiosarcoma Drug Details: RP-1 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Melphalan Hydrochloride in Bile Duct Cancer (Cholangiocarcinoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Melphalan Hydrochloride in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: Melphalan hydrochloride (Hepzato Kit) is a...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Melphalan Hydrochloride in Ocular Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Melphalan Hydrochloride in Ocular Melanoma Drug Details: Melphalan hydrochloride (Hepzato Kit) is a phenylpropanoic acid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Squamous Cell Carcinoma Drug Details: RP-1 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Defibrotide Sodium in Beta Thalassaemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Defibrotide Sodium in Beta Thalassaemia Drug Details: Defibrotide sodium (Noravid, Defitelio, Dinelasi, Prociclide) is a...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Anakinra in Intracerebral Hemorrhage
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Anakinra in Intracerebral Hemorrhage Drug Details: Anakinra (Kineret) is an immunosuppressant produced in Escherichia coli...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.